NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QELBREE (viloxazine hydrochloride) is an extended-release oral capsule approved in April 2021 for attention-deficit/hyperactivity disorder (ADHD). It is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine availability in the central nervous system. This non-stimulant mechanism differentiates it from traditional amphetamine-based ADHD treatments.
$0.004BPart D
Peak8.4 years to LOEProduct is at peak lifecycle with modest Part D claims (7,011 in 2023), indicating a niche market position with stable but limited commercial momentum.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QELBREE at peak lifecycle offers career opportunities in commercial execution, payer engagement, and field sales within the ADHD market segment. Working on this product means driving market penetration in a niche therapeutic area with differentiated non-stimulant positioning against established competitors.
Brand ManagerField Sales Representative
Worked on QELBREE at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.